Abrdn Life Sciences Investors (HQL)

$13.8199

-0.05

(-0.36%)

Market is closed - opens 7 PM, 17 Jun 2024

Insights on Abrdn Life Sciences Investors

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 964.64 → 29.56M (in $), with an average increase of 83.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 33.80M → -11.45M (in $), with an average decrease of 133.9% per quarter

  • Vs KKR

    In the last 1 year, Kkr & Co. L.p. has given 86.3% return, outperforming this stock by 86.4%

  • Vs APO

    In the last 3 years, Apollo Asset Management Inc has given 96.0% return, outperforming this stock by 129.7%

Performance

  • $13.81
    $13.89
    $13.82
    downward going graph

    0.07%

    Downside

    Day's Volatility :0.58%

    Upside

    0.5%

    downward going graph
  • $10.39
    $13.95
    $13.82
    downward going graph

    24.82%

    Downside

    52 Weeks Volatility :25.52%

    Upside

    0.93%

    downward going graph

Returns

PeriodAbrdn Life Sciences InvestorsRussel 2000Index (Russel 2000)
3 Months
3.29%
0.0%
0.0%
6 Months
5.09%
0.0%
0.0%
1 Year
0.44%
0.0%
0.0%
3 Years
-33.62%
-23.8%
-23.8%

Highlights

Market Capitalization
378.3M
Book Value
$16.13
Dividend Share
1.3
Dividend Yield
10.74%
Earnings Per Share (EPS)
1.34
PE Ratio
10.32
PEG Ratio
0.0
Profit Margin
156.45%
Operating Margin TTM
-31.63%
Return On Assets TTM
-0.32%
Return On Equity TTM
1.28%
Revenue TTM
3.5M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
7.000000000000001%
Gross Profit TTM
3.0M
Diluted Eps TTM
1.34
Quarterly Earnings Growth YOY
0.43
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Technicals Summary

Sell

Neutral

Buy

Abrdn Life Sciences Investors is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Abrdn Life Sciences Investors
Abrdn Life Sciences Investors
-3.15%
5.09%
0.44%
-33.62%
-15.63%
Blackstone Inc
Blackstone Inc
-5.18%
-3.74%
33.05%
23.12%
174.07%
Kkr & Co. L.p.
Kkr & Co. L.p.
4.83%
29.25%
90.87%
91.44%
364.2%
Blackrock, Inc.
Blackrock, Inc.
-4.75%
-3.4%
9.47%
-11.51%
74.8%
Apollo Asset Management Inc
Apollo Asset Management Inc
2.79%
23.16%
50.32%
97.83%
248.38%
Brookfield Corp
Brookfield Corp
-8.27%
6.56%
22.09%
-18.34%
30.28%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Abrdn Life Sciences Investors
Abrdn Life Sciences Investors
10.32
10.32
0.0
0.0
0.01
0.0
0.11
16.13
Blackstone Inc
Blackstone Inc
42.56
42.56
1.75
4.77
0.21
0.09
0.03
9.16
Kkr & Co. L.p.
Kkr & Co. L.p.
24.28
24.28
1.3
4.71
0.11
0.02
0.01
24.2
Blackrock, Inc.
Blackrock, Inc.
19.57
19.57
2.46
41.39
0.15
0.03
0.03
267.04
Apollo Asset Management Inc
Apollo Asset Management Inc
12.9
12.9
1.37
7.53
0.3
0.02
0.02
23.53
Brookfield Corp
Brookfield Corp
68.35
68.35
NA
4.58
0.03
0.02
0.01
26.75
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Abrdn Life Sciences Investors
Abrdn Life Sciences Investors
NA
$378.3M
-15.63%
10.32
156.45%
Blackstone Inc
Blackstone Inc
Hold
$146.1B
174.07%
42.56
21.68%
Kkr & Co. L.p.
Kkr & Co. L.p.
Buy
$100.1B
364.2%
24.28
15.64%
Blackrock, Inc.
Blackrock, Inc.
Buy
$114.4B
74.8%
19.57
32.26%
Apollo Asset Management Inc
Apollo Asset Management Inc
Buy
$65.3B
248.38%
12.9
16.23%
Brookfield Corp
Brookfield Corp
Buy
$63.6B
30.28%
68.35
1.14%

Company Information

tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form

Organization
Abrdn Life Sciences Investors
Employees
0
CEO
Dr. Daniel R. Omstead M.S, Ph.D.
Industry
Miscellaneous

FAQs